Any clinical benefit from the use of oncofoetal markers in the management of chemotherapy for patients with metastatic colorectal carcinomas?

Clinical Oncology

Volumn 16, Issue 3, 2004, Pages 196-203

  Trillet Lenoir, Véronique ^a,b   Chapuis, F ^c   Touzet, S ^c   Barbier, J Y ^a   Freyer, G ^a,b   Gaudin, J L ^d   Lombard Bohas, C ^e   Valette, P J ^e   Lledo, G ^f   Gouttebel, M C ^g   Boyer, J D ^h   Chassignol, L ^g   Hamon, H ⁱ   Claudel Bonvoisin, S ^a   Leprince, E ^j   Amoyal, P ^j   Glehen, O ^a,b   Darnand, P ^a   Heilmann, M O ^a   Bleuse, J P ^k  

^a CENTRE HOSPITALIER LYON SUD   (France)

^b UNIVERSITÉ LYON 1   (France)

^c HOSPICES CIVILS DE LYON   (France)

^d CROIX ROUSSE HOSPITAL   (France)

^e EDOUARD HERRIOT HOSPITAL   (France)

^f Clinique Saint Jean   (France)

^g CENTRE HOSPITALIER   (France)

^h Centre Hospitalier Lucien Hussel   (France)

ⁱ CENTRE HOSPITALIER DE VALENCE   (France)

^j CLINIQUE PASTEUR   (France)

^k SANOFI   (France)

more..

Author keywords

CA 19 9; CEA; Chemotherapy; Colorectal cancer

Indexed keywords

CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; FLUOROURACIL; IRINOTECAN; ONCOFETAL ANTIGEN; OXALIPLATIN; RALTITREXED; TUMOR MARKER;

AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; COLORECTAL CARCINOMA; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; DRUG RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; PREDICTION; PRIORITY JOURNAL; RADIODIAGNOSIS; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; STATISTICAL ANALYSIS; WHOLE BODY SCINTISCANNING;

EID: 2342427363     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2003.11.005     Document Type: Article

References (23)

1. Therasse P, Arbuck SG, Eisenhauer E, et al. New guidelines to evaluate the response to treatment in solid tumours. J Natl Cancer Inst 2000;92:205-216.
2. Chezmar JL, Rumancik WM, Megibow AJ, et al. Liver and abdominal screening in patients with cancer: CT versus MRI imaging. Radiology 1988;168:43-47.
3. Warr D, Mc Kinney S, Tannock I. Influence of measurement error on assessment of response to anticancer therapy: proposal for new criteria of tumor response. J Clin Oncol 1984;2:1040-1046.
4. Thiesse P, Ollivier L, Di Stefano-Louineau, D, et al., for the Groupe Français d'Immunothérapie of the Fé dération Nationale des Centres de lutte contre le Cancer. Response rate accuracy in oncology trials: reasons for interobserver variability. J Clin Oncol 1997;15:3507-3514
5. Jonker DJ, Maroun JA, Kocha W. Survival benefit of chemotherapy in metastatic colorectal cancer: a meta-analysis of randomized controlled trials. Br J Cancer 2000;82:1789-1794.
6. Graf W, Pahlman L, Bergström R, et al. The relationship between an objective response to chemotherapy and survival in advanced colorectal cancer. Br J Cancer 1994;70:559-563.
7. Buyse M, Thirion P, Carlson RW, et al., for the Meta-analysis Group in cancer. Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Lancet 2000;356:373-378.
8. Allen-Mersch TG, Kemeny N, Niedzwiecki D, et al. Significance of a fall in serum CEA concentration in patients treated with cytotoxic chemotherapy for disseminated colo-rectal cancer. Gut 1987; 28:1625-1629.
9. Shani A, O'Connell M, Moertel C, et al. Serial plasma carcino-embryonic antigen measurements in the management of metastatic colorectal carcinoma. Ann Intern Med 1978;88:627-630.
10. Kouri M, Pyrhönen S, Kuusela P. Elevated CA 19-9 as the most significant prognostic factor in advanced colorectal carcinoma. J Surg Oncol 1992;49:78-85.
11. Herrera MA, Ming Chu T, Holyoke ED, et al. CEA monitoring of palliative treatment for colorectal carcinoma. Ann Surg 1997; 185:23-30.
12. Ward U, Primrose JN, Finan PJ, et al. The use of tumour markers CEA, CA-195 and CA-242 in evaluating the response to chemotherapy in patients with advanced colorectal cancer. Br J Cancer 1993;67:1132-1135.
13. Tsavaris N, Vonorta K, Tsoutsos H, et al. Carcinoembryonic antigen (CEA), alpha-fetoprotein, CA 19-9 and CA 125 in advanced colorectal cancer (ACC). Int J Biol Markers 1993; 8:88-93.
14. Rothenberg ML, Cox JV, DeVore RF, et al. A multicenter, phase II trial of weekly irinotecan (CPT 11) in patients with previously treated colorectal carcinoma. Cancer 1999;85:786-795.
15. Hanke B, Riedel C, Lampert S, et al. CEA and CA 19-9 measurement as a monitoring parameter in metastatic colorectal cancer (CRC) under palliative first-line chemotherapy with weekly 24-hour infusion of high-dose 5-fluorouracil (5-FU) and folinic acid (FA). Ann Oncol 2001;12:221-226.
16. Anonymous. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. J Clin Oncol 1996; 14:2843-2877.
17. Bast RC, Ravdin P, Hayes DF, et al. Update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001;19:1865-1878.
18. Maughan TS, James RD, Kerr DJ, et al. Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicenter randomised trial. Lancet 2003; 361:457-464.
19. de Gramont A, Bosset JF, Milan C, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 1997;15:808-815.
20. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-2947.
21. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000;355:1041-1047.
22. Cunningham D. Mature results from three large controlled studies with raltitrexed ('Tomudex'). Br J Cancer 1998;77:15-21.
23. Trillet-Lenoir V, Freyer G, Kaemmerlen P, et al. Assessment of tumour response to chemotherapy for metastatic colorectal cancer. Accuracy of the RECIST criteria. Br J Radiol 2002;75:903-908.